Drugs & Targets Oncopeptides to submit NDA for melflufen in multiple myeloma May 24, 2019Vol.45 No.21
Drugs & Targets FDA approves Bavencio + Inlyta combination in renal cell carcinoma May 17, 2019Vol.45 No.20
Drugs & Targets GE Healthcare and Indi Molecular partner on diagnostic tool for immunotherapy patients May 17, 2019Vol.45 No.20
Drugs & Targets FDA grants Breakthrough Device designation to Natera’s Signatera test May 10, 2019Vol.45 No.19
Drugs & Targets Caris Life Sciences receives FDA Breakthrough Device designation for MI Transcriptome companion diagnostic test May 10, 2019Vol.45 No.19
Drugs & Targets European Commission approves Lorviqua in previously-treated ALK-positive advanced NSCLC May 10, 2019Vol.45 No.19
